Fenoxaprop-ethyl API Manufacturers
compare suppliers & get competitive offers
Join our notification list by following this page.
Click the button below to find out more
Click the button below to switch over to the contract services area of Pharmaoffer.
Looking for Fenoxaprop-ethyl API 66441-23-4?
- Description:
- Here you will find a list of producers, manufacturers and distributors of Fenoxaprop-ethyl. You can filter on certificates such as GMP, FDA, CEP, Written Confirmation and more. Send inquiries for free and get in direct contact with the supplier of your choice.
- API | Excipient name:
- Fenoxaprop-ethyl
- Synonyms:
- Fenoxaprop ethyl
- Cas Number:
- 66441-23-4
- DrugBank number:
- DB05252
- Unique Ingredient Identifier:
- 7U20WEM458
General Description:
Fenoxaprop-ethyl, identified by CAS number 66441-23-4, is a notable compound with significant therapeutic applications. Fenoxaprop-ethyl (organic nitrate combined with L-arginine), is an oral proprietary nitrate therapeutic shown to induce coronary vasodilation while overcoming the significant problem of drug tolerance. Fenoxaprop-ethyl has been investigated to treat chronic angina, the chest pain that occurs from inadequate blood flow to the coronary arteries around the heart.
Indications:
This drug is primarily indicated for: Chronic angina and Coronary Artery Disease. Its use in specific medical scenarios underscores its importance in the therapeutic landscape.
Mechanism of Action:
Fenoxaprop-ethyl functions by: Fenoxaprop-ethyl is a proprietary combination of nitrate and L-arginine that provides the beneficial cardiovascular effects of nitrates. Combining L-arginine with organic nitrates prevents the endothelial cell's depletion of L-arginine and the associated problem of nitrate tolerance. By eliminating nitrate tolerance, Fenoxaprop-ethyl allows patients to receive the continuous, 24-hour benefit of a potent nitrate product, thus sustaining the desired vasodilation effect. This mechanism highlights the drug's role in inhibiting or promoting specific biological pathways, contributing to its therapeutic effects.
Classification:
Fenoxaprop-ethyl belongs to the class of organic compounds known as 2-phenoxypropionic acid esters. These are aromatic compounds hat contain a phenol ether attached to the C2-atom of a phenylpropionic acid ester, classified under the direct parent group 2-phenoxypropionic acid esters. This compound is a part of the Organic compounds, falling under the Benzenoids superclass, and categorized within the Benzene and substituted derivatives class, specifically within the 2-phenoxypropionic acid esters subclass.
Categories:
Fenoxaprop-ethyl is categorized under the following therapeutic classes: Acids, Acyclic, Agrochemicals, Compounds used in a research, industrial, or household setting, Fatty Acids, Fatty Acids, Volatile, Herbicides, Lipids, Pesticides, Toxic Actions. These classifications highlight the drug's diverse therapeutic applications and its importance in treating various conditions.
Fenoxaprop-ethyl is a type of Anti-anginal agents
Anti-anginal agents are a category of pharmaceutical active pharmaceutical ingredients (APIs) used for the treatment of angina, a condition characterized by chest pain or discomfort caused by reduced blood flow to the heart muscle. These APIs target the underlying cause of angina, which is often related to insufficient blood supply to the heart.
One commonly used anti-anginal agent is nitroglycerin, which belongs to the class of organic nitrates. Nitroglycerin works by dilating blood vessels, including the coronary arteries that supply blood to the heart. This dilation improves blood flow to the heart, relieving chest pain and reducing the workload on the heart.
Another class of anti-anginal agents is calcium channel blockers (CCBs). CCBs inhibit the movement of calcium ions into heart muscle cells and blood vessel walls. By doing so, they relax and widen blood vessels, enhancing blood flow to the heart and reducing the frequency and severity of angina episodes.
Beta blockers are also commonly used in the treatment of angina. These agents block the effects of adrenaline and other stress hormones on the heart, resulting in reduced heart rate and blood pressure. By slowing down the heart's activity, beta blockers decrease the demand for oxygen and reduce angina symptoms.
Anti-anginal agents play a crucial role in managing angina, providing relief to patients and improving their quality of life. It is important to consult with healthcare professionals for proper diagnosis, prescription, and usage of these pharmaceutical APIs to ensure safe and effective treatment of angina.
